Licensing & Market Access
A licensed asset is only worth its market
Most licensing conversations start with the molecule. We start with whether it can be registered where you intend to sell it, and whether anyone there will pay for it. Both questions are cheaper to answer before the term sheet than after.
How we work
Screening first, matchmaking second
Conventional licensing runs on relationships. A dealmaker proposes counterparties from personal knowledge, and the regulatory and reimbursement questions surface later — usually during diligence, sometimes after signature.
We invert that. Candidates come from continuously maintained matrices rather than from memory, and the registration pathway and reimbursement feasibility are screened as part of the shortlist rather than as a diligence afterthought.
The result is a shorter list with a better reason behind each name, and far fewer deals that fail on something that was knowable from the start.
The sequence
From screening to launch
Six stages, run in this order for a reason. Each one either kills a bad idea cheaply or increases confidence in a good one before more money is committed.
- 01
Project screening
The asset, indication, development stage and territory ambition are established, along with what a successful deal would have to look like commercially. A vague brief produces a long shortlist that helps nobody.
- 02
AI-assisted matching
Candidates are drawn from the customer matrix and constrained by what the product matrix says about crowding and exclusivity in each target market. Each name arrives with a stated rationale, not just a logo.
Powered by AI Intelligence Platform - 03
Registration pathway planning
Filing routes are assessed against the intended launch sequence. A gap analysis establishes what the existing data package supports, which is what turns a hoped-for timeline into a defensible one.
Powered by Global Registration - 04
HTA pre-assessment
Comparator expectations, endpoint acceptability and the pricing environment are screened per market. A product can be approvable and still commercially dead, and that is worth knowing before the valuation is agreed.
Powered by HTA Pre-Assessment - 05
Transaction execution
Terms, milestones, territory carve-outs and responsibility splits are negotiated, and the agreements are drafted or reviewed so that obligations on both sides are unambiguous.
- 06
Post-deal implementation
Filing, technology transfer, supply setup and launch support continue under the same program plan, so the asset actually reaches the market rather than stalling after signature.
Powered by FSO+ Program
Two lines
What we license
In-licensing & out-licensing of IP
New Drug Candidates
Clinical-stage assets from preclinical through Phase III, matched on therapeutic fit, territory rights and development stage — and screened for whether the registration and reimbursement case holds in the markets you actually want.
Market access & commercial licensing
Finished Dosage Form
Registered and registrable finished products matched to partners with the commercial infrastructure to launch them, with market entry strategy, regulatory compliance and post-collaboration support handled as part of the program.
Questions
Frequently asked
Yes. We support in-licensing and out-licensing, though not on both sides of the same transaction. Which side we act for is agreed and documented before any counterparty is approached.
Bring us an asset or a gap in your portfolio
Tell us what you are looking to license in or out and which territories matter. You will get a screened view of feasibility before anyone is approached.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →